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Two cases of necrotizing keratitis following laser refractive corneal surgery, with stable and 
controlled Crohn’s disease are described. A 40-year-old woman developed bilateral stromal 
inflammation and inferior thinning in the right eye along the flap edge within 1 day of 
uneventful bilateral IntraLase laser-assisted in situ keratomileusis. The other case is a 30-
year-old man who also developed bilateral inferior stromal infiltrates 2 days following 
photorefractive keratectomy. Both cases were aggressively treated with systemic and topical 
corticosteroids. The infiltrates in both patients gradually resolved, with one relapse during 
the 7 months period of follow-up in the first case. These cases highlight the importance of 
taking precautions considering this and similar autoimmune conditions as a relative 
contraindication to refractive surgery. 
 
Introduction 
Inflammatory bowel diseases (IBD) include ulcerative colitis (UC) and Crohn’s 
disease (CD). These are chronic inflammatory conditions affecting the gastrointestinal 
tract characterized by the presence of extensive ulcerations in the intestines. The 
pathogenesis of IBD is hypothesized to involve an abnormal immune response to 
environmental antigens in a person who is already genetically predisposed. A vast 
majority of these patients develop intestinal complications, with both high incidences 
of endoscopic recurrence and symptomatic recurrence. It is reported that ocular  
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surgery in IBD and other autoimmune disorders can trigger ocular complications, such 
as corneal infiltrates, ulcerations and necrotizing inflammations [1, 2]. Other ocular 
complications include scleritis, episcleritis, ulcerative keratitis, corneal infiltrates, 
uveitis, vasculitis, and optic neuritis. A few studies have demonstrated that laser-
assisted in situ keratomileusis (LASIK) can be performed effectively and safely in 
selected patients with stable and controlled IBD, including CD [3, 4]. Successful 
treatments of refractive conditions for patients with IBD and other autoimmune 
conditions using photorefractive keratectomy (PRK) and IntraLase LASIK have been 
reported, with a postoperative corneal complication rate no greater than for patients 
without these conditions. Due to the potential for ocular complications in some 
patients, IBD and other autoimmune conditions are considered to be a relative 
contraindication to laser refractive surgery. 
In this paper, we describe two case reports of PRK and IntraLase LASIK procedures 
in individuals with IBD in long-term remission that developed infiltrates post IntraLase 
LASIK in the first case and necrotizing keratitis along the flap incision site post PRK in 
the second case. 
Case Report 1 
A 40-year-old woman presented for refractive surgery assessment at the Gimbel Eye Centre, 
Calgary, Canada, in May 2010. The patient had worn contact lenses for the last 22 years and now was 
becoming intolerant due to dryness. She had CD, which had been in remission for the last 3 years. She 
was not on any medications and denied having any ocular pathology in the past. A complete eye 
examination was performed to screen for any ocular pathology and determine her candidacy for 
refractive surgery.  
The manifest refraction was –3.75 –0.75 × 121 in the right eye and –4.25 –0.25 × 177 in the left 
eye, achieving a corrected distance visual acuity of 20/20 in both eyes. Keratometry (diopters) was 
44.75 @ 149/45.50 @ 59 in the right eye and 45.0 @ 180/45.50 @ 90 in the left eye. The central 
corneal thickness was 537 µm in the right eye and 522 µm in the left eye. The patient was considered 
suitable for IntraLase LASIK, targeting both eyes for distance. 
An IntraLase FS laser (Abbot Medical Optics, Abbott Park, Ill., USA) was used to create corneal 
flaps with a depth of 120 µm and diameter of 8.8 mm with a superior hinge, sequentially in both eyes. 
The ablation was then performed using a wave-front optimized aspheric transition zone ablation 
pattern with NIDEK EC 5000 CX3 excimer laser (NIDEK, Gamagori, Japan) with a treatment zone of 5 
and 9 mm transition zone. The target refraction was emmetropia in both eyes. The IntraLase LASIK 
procedure was uneventful in both eyes. 
She presented the next day with symmetrical corneal infiltrates at the flap edge at 10 and 2 o’clock, 
1 mm in diameter, surrounding trace inflammatory cells and no overlying epithelial defects. She was 
started on prednisolone (Pred Forte) 1.0% ophthalmic solution every hour and moxifloxacin HCl 
(Vigamox) 0.5% six times per day in both eyes. Over the next few days, she was monitored closely and 
the corneal lesions appeared to be resolving. Her uncorrected visual acuity (UCVA) fluctuated 
between 20/15 and 20/25 in both eyes, as expected from early IntraLase LASIK healing. One week 
postoperatively, she had deterioration in the clinical appearance of her corneas. A slit lamp 
examination showed new infiltrates at the flap edge inferiorly in the right eye (fig. 1). The left eye also 
showed new infiltrates superiorly. A clear interval was seen between the infiltrates and the limbus, 
and the center in both eyes. The interface remained clear. 
The patient’s topical treatment was changed to preservative free prednisolone sodium phosphate 
0.5% drops hourly, and Vigamox 0.5% was continued at six times per day. In the absence of any 
clinical signs of infective keratitis, autoimmune-related necrotizing keratitis was diagnosed in both  
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eyes. Oral prednisolone 80 mg daily, omiprazole 20 mg daily and doxycycline 100 mg twice a day, 
were also started. 
The patient was monitored on a daily basis. The systemic and topical treatment led to a significant 
improvement, with gradual resolution of flap infiltrates over the next 4 weeks. There remained a faint 
haze at the site of the original infiltrates. The topical steroid preparation was tapered over the next 4 
weeks, and the oral steroid was tapered by 5 mg every 1 week. 
At 2 months follow-up, five new infiltrates, each 1 mm in diameter were noticed at the right eye 
flap hinge. No overlying epithelial defect or thinning was seen. Tobramycine 0.3%/dexamethasone 
0.1% (Tobradex) eye drops were started in the right eye. The patient was advised to continue with 
oral prednisolone 10 mg daily, omiprazole 20 mg daily and doxycycline 100 mg daily. The recurrent 
infiltrate in the right eye gradually cleared over the next week. The Tobradex 0.3% eye drops were 
tapered off gradually for the next 2 weeks, and oral medications were also gradually tapered and 
stopped in the next 4 weeks. 
Seven months postoperatively, the UCVA was 20/15–2 in both eyes, and the manifest refraction 
was +0.25 spherical in both eyes. A slit lamp examination showed an area of subtle sub-epithelial haze 
at the temporal aspect of the flap incision (fig. 2). No residual haze or corneal defects were seen in the 
left eye. 
Case Report 2 
A 30-year-old man referred by his optometrist due to his inability to wear contact lenses following 
an episode 1 year before of infiltrates in the right cornea and peripheral corneal ulcer in the left eye. 
The patient was not happy with his glasses wear, as he could not wear contact lenses due to dryness 
and risk of recurrent corneal infection. He had CD, which was in remission with no systemic 
complaints and no medications for the past 10 years. An eye examination revealed bilateral faint old 
scars in the inferior peripheral corneas. 
The manifest refraction was –7.00 –0.25 × 96 in the right eye and –7.75 –0.25 × 52 in the left eye, 
achieving a corrected distance visual acuity of 20/15 in both eyes. Keratometry (diopters) was 44.25 
@ 113/44.50 @ 23 in the right eye and 44.75 @ 70/45.00 @ 160 in the left eye. The central corneal 
thickness was 571 µm in the right eye and 576 µm in the left eye. Detailed preoperative discussion 
about the risk of recurrent corneal inflammation with a corneal laser refractive procedure, i.e. PRK 
and the I LASIK keratomileusis was undertaken. He was also given the choice of intraocular phakic 
corrective lenses. However, the patient opted for the PRK in view of his active contact sport activities. 
PRK surface ablation was performed sequentially, using optimized aspheric transition zone 
ablation pattern with NIDEK EC 5000 CX3 excimer laser with a treatment zone of 5 and 8 mm 
transition zone. The surface epithelium was removed prior with an Amoils epithelial scrubber 
(Innovative Excimer Solutions, Toronto, Ont., Canada). The target refraction was emmetropia in both 
eyes. The PRK procedure was uneventful in both eyes. 
He presented the second day with inferior corneal infiltrates, near the limbus at 5:30 and 7 o’clock, 
in the right and left eye, respectively (fig. 3). He was started on fluorometholone (FML) 0.1% 
ophthalmic solution and gatifloxacin (Zymar) 0.3% every 2 h in both eyes. His UCVA fluctuated 
between 20/20 and 20/30 in both eyes, as expected from early PRK healing. One week 
postoperatively, he had a deterioration of his clinical appearance. A slit lamp examination showed 
new infiltrates superiorly extending from 10:30 to 12:30 o’clock, 1 mm from the limbus, and inferior 
confluent area of epithelial defect from 5 to 8:30 o’clock, 1 mm from the limbus. The left eye also 
showed new infiltrates at 7 o’clock with overlying epithelial thinning. 
The patient’s topical treatment was changed to Pred Forte 1.0% eye drops in the right eye and 
advised to continue FML 0.1% four times a day in the left eye. Oral prednisolone 80 mg daily, 
ranitidine 150 mg twice daily, and doxycycline 100 mg daily were also started. With this treatment 
regime, the new corneal infiltrates in both eyes gradually resolved in 4 weeks. The oral steroid was 
gradually tapered off with 5 mg less every fifth day.  
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Three months postoperatively, the UCVA was 20/15 in the right eye and 20/25 in the left eye, and 
the manifest refraction was +0.25 –0.50 × 87 and +2.00 –1.00 × 47, respectively. A slit lamp 
examination showed areas of subtle sub-epithelial haze superiorly and inferiorly in the right eye and 
only inferiorly in the left eye. The patient was advised to continue FML 0.1% four times a day in both 
eyes and to have the corneal haze monitored regularly by his local optometrist. In the last ocular 
exam, at 8 months postoperatively by his optometrist, the UCVA was 20/20 in the right eye and 
20/20–2 in the left eye, and the manifest refraction was +0.25 +0.25 × 90 and +1.00 –0.75 × 25, 
respectively. The subtle sub-epithelial haze had resolved with faint inferior sub-epithelial scars in 
both eyes, and the patient was taken off the FML 0.1% by his optometrist. 
Discussion 
UC and CD are classified as IBD, which represents a relative contraindication to 
refractive corneal surgery.  
Successful outcomes without ocular complications post refractive corneal surgery 
have been reported in the literature in patients with IBD [3, 4]. Our center has 
encountered two cases of corneal necrotizing keratitis following corneal refractive 
surgery in patients with IBD. A case of surgically induced corneal necrotizing keratitis 
following LASIK in a patient with CD has been reported in the literature [5]. Our first 
case is similar to the reported case, having infiltrates that were well defined and 
straddling the flap edges. There was also no interface haze or granularity, 
differentiating it from diffuse lamellar keratitis. At a later stage, there was mild inferior 
flap margin thinning only in the right eye, but no overlying epithelial ulceration. No 
conjunctival and episcleral inflammation was noticed in either eye. This could be due to 
aggressive topical and systemic steroid treatment initiated early, in light of the 
previously reported case. 
IBD presents more frequently in the second and third decades of life. Ocular 
complications in IBD can be primary or secondary to systemic complications [6]. 
Episcleritis, scleritis, and uveitis are reported to be the frequent primary complications 
[7]. In comparison to the spondyloarthropathies, IBD patients were female and had 
uveitis that was bilateral, posterior, insidious in onset, or chronic in duration; 
episcleritis, scleritis, and glaucoma are also more common [8]. Other reported primary 
ocular complications are conjunctivitis, proptosis, idiopathic orbital inflammation, 
extraocular muscle pareses, myositis, orbital cellulitis, peripheral corneal ulcers, 
macular edema, central serous retinopathy, retrobulbar neuritis, optic neuropathies, 
bilateral neuroretinitis with secondary vitritis, subretinal fibrosis and panuveitis 
syndrome, multifocal choroiditis, and pars planitis [9–12]. Secondary ocular 
complications in IBD are due to malnutrition and ileal resection. These can result in 
Candida endophthalmitis (parenteral nutrition), decreased tear formation, night 
blindness (hypovitaminosis A), and cataract (corticosteroid therapy). 
Ocular treatment should be started with simultaneous gastroenterologic 
consultation. Treatment for anterior uveitis and scleritis includes topical steroids and 
nonsteroidal anti-inflammatory drugs, if approved by the gastroenterologist. Short-
term, systemic corticosteroids are given for severe inflammation not responding to the 
topical steroids. For posterior uveitis or cystoid macular edema, intravitreal steroids or 
a fluocinolone acetonide implant can also be used [13, 14]. In resistant cases with 
persistent inflammation, cytotoxic immunosuppressive agents (hydroxychloroquine,  
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cyclophosphamide, and azathioprine) [15] and cyclosporine can be also considered. In 
our two cases, we chose to use both topical and systemic corticosteroids with good final 
visual and structural outcomes. 
When making the decision to operate on these patients, one needs to consider the 
disease process as the two afore-mentioned cases were cases of IBD in remission for 
several years without any recent flare-ups, yet they both developed features of 
necrotizing keratitis. For surgeons, who decide to operate on these patients, a careful 
follow-up is warranted, as these patients may develop sight-threatening complications. 
In our experience, it was the careful follow-up management, which led to a successful 
outcome maintaining excellent vision. 
In conclusion, both PRK and LASIK can be considered to be reasonable surgical 
options in selected patients with stable and controlled IBD including CD, resulting in 
favorable postoperative refractive outcome. 
Disclosure Statement 







Fig. 1. Slit-lamp photograph of post IntraLase LASIK corneal infiltrates at the flap edge inferiorly of 
the right eye. a Low magnification. b High magnification. 
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Fig. 2. Slit-lamp photograph of the right eye post treatment at 7 months (a), with subtle sub-epithelial 




Fig. 3. Slit-lamp photograph of inferior corneal infiltrates post PRK in each eye. 
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